GeoVax Labs, Inc. (GOVX) News
Filter GOVX News Items
GOVX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GOVX News Highlights
- For GOVX, its 30 day story count is now at 3.
- Over the past 22 days, the trend for GOVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GOVX are DEC.
Latest GOVX News From Around the Web
Below are the latest news stories about GEOVAX LABS INC that investors may wish to consider to help them evaluate GOVX as an investment opportunity.
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024. Presentation Details:Presenter: David Dodd, Chairman & CEODate/Time: January 8, 2023, 2:30 pm PS |
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax’s development of a |
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register NowMIAMI, Dec. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emerging Growth Conference on December 6th and 7th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting |
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus. The data were presented during the World Vaccine Congress, West Coast conference, bein |
GeoVax to Participate in Upcoming December Investor EventsATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its senior management will participate in two upcoming investor events: NobleCon19, December 3-5, 2023, Boca Raton, FLDate/Time: December 4, 2023 at 10:00 a.m. ETPresentation Topic: Corporate Overview and UpdateSpeaker: David Dodd, Chairman & CEO Noble Capital Markets’ Nine |
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressPresentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from the active development program for its next-generation COVID-19 vaccin |
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine. The data were presented during the Vaccines Summit 2023 conference, being held in Bost |
GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call TranscriptGeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call Transcript November 8, 2023 GeoVax Labs, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.17. Operator: Good afternoon, and welcome everyone to the GeoVax Third Quarter 2023 Corporate Update Call. My name is Mandeep and I will facilitate today’s call. With me are […] |
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateSignificant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference showing safe administration and tumor reduction Multi-Product License Secured for ProBioGen's AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities of MVA-based vaccine portfolio Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Nov. 08, 202 |
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register NowMIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |